Novartis Novel STAMP Inhibitor Passes First Phase III Test In CML
Asciminib Could Be New Option For Resistant Patients
Phase III data for asciminib suggest it could provide a new avenue of therapy for chronic myeloid leukemia patients who are running out of treatment options.
